An interventional study of No Interventions in Long COVID Syndrome, sponsored by Institut National de la Santé Et de la Recherche Médicale, France. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Institut National de la Santé Et de la Recherche Médicale, France · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Post-Acute COVID-19 Syndrome with a site in France — 5 open to participants now, 5 under way, none of them phase 3. Post-Acute COVID-19 Syndrome · France.
Among the 16 studies in Post-Acute COVID-19 Syndrome with a site in France, this one is one of 3 that started in 2023, is one of 6 with no phase, and was the 14th registered.
605 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.
Browse Post-Acute COVID-19 Syndrome studies →5 of the 16 studies in Post-Acute COVID-19 Syndrome with a site in France are open now. Recruiting first, the newest first:
Hospices Civils de Lyon · Sites in France
Ages 18+
Centre Hospitalier Universitaire de la Réunion · Sites in France
Ages 18+
Centre Hospitalier Universitaire de Nice · Sites in France
Ages 18+ · Healthy volunteers
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–80
Central Hospital, Nancy, France · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 145 Post-Acute COVID-19 Syndrome studies recruiting now, 70 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 3 started in 2023.
This study's enrollment of 618 is above the median of 60 across 417 interventional studies indexed under Post-Acute COVID-19 Syndrome.
Median enrollment 131 across the 6 interventional studies, 501 across the 10 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 16 has an industry lead sponsor. The 10 most frequent:
Institut National de la Santé Et de la Recherche Médicale, France is the lead sponsor of 378 studies on the registry; 81 are open to participants now.
Institut National de la Santé Et de la Recherche Médicale, France has 1 study filed under Post-Acute COVID-19 Syndrome — fewer than ten, so there is no comparison to draw.
1 of the studies in Post-Acute COVID-19 Syndrome with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05851859Centre Hospitalier Universitaire de la RéunionEvaluation of the Effectiveness of Breathing Control Technique on Long COVID Symptoms at the Reunion University Hospital | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies in Post-Acute COVID-19 Syndrome with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The term "long COVID" refers to persistent, recurrent, or newly emerging symptoms following a biologically confirmed or suspected case of COVID-19 that are still present three months after the acute episode or positive test result, and that cannot be explained by a complication of the acute phase, a flare-up of a comorbid condition, or any cause other than COVID-19. The incidence of long Covid has primarily been estimated through the follow-up of cohorts of patients initially treated in the hospital, sometimes based on cohorts of patients who consulted a primary care physician, and rarely based on cohorts of individuals from an unselected source population who tested positive for Covid-19. Currently, there is little data available to estimate its overall burden in primary care and the general population (prevalence, incidence, healthcare utilization, symptom progression, and impact on quality of life). This study will consist of two arms: "general practice" and "general population." For each arm, an initial phase will involve simply counting cases, and a second phase will involve describing and monitoring cases over the course of one year, focusing on clinical outcomes, quality of life, and the patient care experience. The "general practice" arm will also include a study of the care experience from the perspective of general practitioners. Statistical analysis. For each arm of the study, the included patients will be described in terms of the various aspects under investigation: sociodemographic characteristics, history of COVID-19 infection, clinical presentation, quality of life, and psychological, professional, and family impact. The incidence and prevalence of cases seen in general practice will be estimated. Expected results and implications. The study will provide a better understanding of the disease and its impact, including for people who do not seek care for this reason. It will provide information to guide public policies regarding the care and treatment pathways for people suffering from long COVID.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
People with long COVID seen in general practice
Other: No Interventions
Individuals with long Covid in the general population
Other: No Interventions
No Interventions
Presence or absence of symptoms
Time frame: At enrollment and after 3, 6, 9 and 12 months
Assessment of the disease's impact on quality of life based on EQ-5D index (EuroQoL-5 Dimensions)
It generally ranges from less than 0 to 1 (perfect health). Higher scores indicate a better quality of life
Time frame: At enrollment and after 3, 6, 9 and 12 months
Assessment of a patient's health status using PROMIS-29 (Patient-Reported Outcomes Measurement Information System)
Clinical interpretation of scores : \> 60 Excellent / high-performing (well above the norm) 55 - 60 above the average 45 - 55 population average (Normal range) 40 - 45 below the average \< 40 Deficient / Problematic (Often requires clinical attention)
Time frame: At enrollment and after 3, 6, 9 and 12 months
Measurement of the severity of generalized anxiety : GAD-7 (Generlized Anxiety Disorder-7) questionnaire
Scores and interpretation : 0-4 very low level of anxiety, 5-9 mild level of anxiety (monitoring or relaxation technique), 10-14 moderate level of anxiety (Complete clinical evaluation is required), 15-21 severe level of anxiety (needs intervention-therapy or treatment)
Time frame: At enrollment and after 3, 6, 9 and 12 months
Assessment of depression by Patient's Health Questionnaire PHQ-9
Used to evaluate the severity of depressive symptoms, giving a total score ranging from 0 to 27. 0-4 : minimal or no deprssive symptoms, 5-9 : mild depression, 10-14 : moderate depression, 15-19 : moderately severe depression, 20-27 : severe depression
Time frame: At enrollment and after 3, 6, 9 and 12 months
Assessment of social support using SSD-12 (Social Support Distress Scale)
SSD-12 focuses on distress resulting from a lack of support or from ineffective support Low score : the patient has sufficient support, limited risk of social distress Moderate score : areas of vulnerability identified High score : high risk of psychological distress, isolation and health complications.
Time frame: At enrollment and after 6 and 12 months
Identification of individuals who may be suffering from Post-Traumatic Stress Disorder (PTSD) using PC-PTSD-5 (Primary Care PTSD Screen for DSM-5)
Used to identify individuals who may be suffering from Post-Traumatic Stress Disorder (PTSD) after experiencing traumatic event 0 - 2 No suspicion of PTSD. 3 or more warning, requires a futher diagnostic evaluation by a specialist (psychologist or psychiastrist
Time frame: At enrollment
Assessment of the impact of the illnesson Patient Social Support
0 : the patient is exactly average of the general population +1 : The patient has significantly above-average social support * 1 : The patient has significantly less social support than average * 2 : The patient is in a position of critical social vulnerability (vry little support compared to the standard)
Time frame: At enrollment and after 6 and 12 months
Assessment of quality of life using EQS-C (European Quality of Life Questionnaire - Cancer)
Designd to assess the quality of life of patients with cancer. Excellent quality of life, low impact of the illess (T \>80 ) Quality of life within the normal range (T between 40 and 60) Significant deterioration in quality of life (T\< 40)
Time frame: At enrollment and after 3, 6, 9 and 12 months
Ran from Jun 2023 to primary completion in Jul 2024, 13 months.
Of 233 non-industry interventional studies with no phase under Post-Acute COVID-19 Syndrome, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's 13 months is below that.
Counting every sponsor, half of 244 studies reached it within 16 months; a quarter within 7 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Post-Acute COVID-19 Syndrome →
Institut National de la Santé Et de la Recherche Médicale, France →